Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX
Observational study · 2022
- What was studied
- CORTEX post-COVID program; 979 patients
- Main finding
- Observational follow-up recorded fatigue, cognitive and other post-COVID complaints and changes during treatment.
Proportion of neurological consultations with post-COVID complaints · 30% · A descriptive consultation figure, not a treatment response
Reported findings and study design
979 post-COVID patients; 674 neurologists contributed. Mean age 54.6 ± 0.45 years. Cortexin 10 or 20 mg IM for ten days; baseline, days 10–14 and day-30 visits.
Population or model CORTEX post-COVID program; 979 patients
Dose, route and schedule
Cortexin: 10 mg or 20 mg intramuscularly during a ten-day course. Administration frequency is not explicit in the indexed abstract.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Proportion of neurological consultations with post-COVID complaints | 30% | A descriptive consultation figure, not a treatment response |
| Dose comparison | 20 mg described as more effective on anxiety-related symptoms | Numerical score differences not supplied |
The abstract contains garbled text about infection duration; it has not been interpreted into a study-duration estimate.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- No randomized untreated control is described.
- Symptom recovery and confounding remain plausible explanations; questionnaires are not wearable sleep stages.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Putilina MV, Mutovina ZY, Kurushina OV, Khalilova DM, Saverskaya EN, Stepanova SB, Khoreva MA, Starikov AS. Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX Zh Nevrol Psikhiatr Im S S Korsakova 122(1):84-90. PMID 35175707
Study source ↗ · DOI 10.17116/jnevro202212201184 · Bibliography entry · Link to this summary